Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Apr;6(4):344-6.
doi: 10.1158/2159-8290.CD-16-0238.

Molecular Mechanism of Mutant CALR-Mediated Transformation

Affiliations
Comment

Molecular Mechanism of Mutant CALR-Mediated Transformation

Robert F Stanley et al. Cancer Discov. 2016 Apr.

Abstract

Elf and colleagues used an elegant series of functional and biochemical assays to investigate the molecular mechanism of mutant calreticulin (CALR)-driven cellular transformation in myeloproliferative neoplasms (MPN). Mutant CALR is sufficient to induce MPN in mouse transplantation experiments, and transformation is dependent upon physical interaction mediated by the positive electrostatic charge of the mutant CALR C-terminal domain and the thrombopoietin receptor MPL.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have any relevant conflicts of interest.

Figures

Figure 1
Figure 1. Schematics of the mechanism of mutant CALR-mediated oncogenic transformation
(1) Frameshift mutations (here: p.L367fs*46) in exon 9 of the calreticulin (CALR) gene codes for mutant CALR (CALRMUT) with a positively charged C-terminal domain instead of the negatively charged C-terminus of wild-type CALR (CALRWT) protein. (2) CALRMUT also lacks the C-terminal endoplasmic reticulum (ER) retention signal (KDEL) present in CALRWT protein. (3) The positive charge of the CALRMUT C-terminus is required for direct binding to the thrombopoietin receptor (MPL). (4),(5) Binding of CALRMUT to MPL is required for downstream JAK-STAT activation and oncogenic transformation. Illustration by Barbara Walter.

Comment on

References

    1. Elf S, AN, Chen E, Perales-Paton J, Rosen EA, Ko A, et al. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 2016 - PMC - PubMed
    1. Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. American journal of hematology. 2016;91:50–8. - PubMed
    1. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270. - PMC - PubMed
    1. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6. - PubMed
    1. Tefferi A, Pardanani A. Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncology. 2015;1:97–105. - PubMed

Publication types